Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
18.55
-0.15 (-0.80%)
At close: Dec 5, 2025, 4:00 PM EST
19.59
+1.04 (5.61%)
After-hours: Dec 5, 2025, 5:40 PM EST
Company Description
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States.
It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD).
Its late-stage investigational once-daily norepinephrine reuptake inhibitor, Ampreloxetine is in the development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA).
It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI.
Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Theravance Biopharma, Inc.
| Country | United States |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 97 |
| CEO | Rick Winningham |
Contact Details
Address: 901 Gateway Boulevard South San Francisco, California 94080 United States | |
| Phone | 650 808 6000 |
| Website | theravance.com |
Stock Details
| Ticker Symbol | TBPH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001583107 |
| CUSIP Number | G8807B106 |
| ISIN Number | KYG8807B1068 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Rick E. Winningham M.B.A. | Chief Executive Officer and Director |
| Aziz Sawaf C.F.A. | Senior Vice President and Chief Financial Officer |
| Brett A. Grimaud Esq. | Senior Vice President, General Counsel and Secretary |
| Stuart Knight | Senior Vice President of IT&I and Chief Information Officer |
| Rhonda F. Farnum | Chief Business Officer and Senior Vice President of Commercial and Medical Affairs |
| Stacy L. Pryce | Senior Vice President and Chief Strategy Officer |
| Dr. Aine Miller Ph.D. | Senior Vice President of Development and Head of Ireland Office |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 3, 2025 | 144 | Filing |
| Nov 26, 2025 | 144 | Filing |
| Nov 12, 2025 | 10-Q | Quarterly Report |
| Nov 12, 2025 | 144 | Filing |
| Nov 10, 2025 | 8-K | Current Report |
| Aug 25, 2025 | 8-K | Current Report |
| Aug 20, 2025 | 8-K | Current Report |
| Aug 13, 2025 | 10-Q | Quarterly Report |
| Aug 12, 2025 | 8-K | Current Report |
| Jul 14, 2025 | 144 | Filing |